Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 133, Issue 1, 2013, Pages 274-276

  Viros, Amaya ^a,b   Hayward, Robert ^a   Martin, Matthew ^a   Yashar, Sharona ^c   Yu, Clarissa C ^c   Sanchez Laorden, Berta ^a   Zambon, Alfonso ^a   Niculescu Duvaz, Dan ^a   Springer, Caroline ^a   Lo, Roger S ^c   Marais, Richard ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUOROURACIL; VEMURAFENIB;

ADVERSE OUTCOME; ENZYME INHIBITION; GENE MUTATION; HUMAN; KERATOACANTHOMA; LETTER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA;

EID: 84872185821     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.268     Document Type: Letter

References (14)

1. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-166
2. Curtis RE, Boice Jr JD, Stovall M et al. (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-511
3. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-544
4. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-199
5. Gray RJ, Meland NB (2000) Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg 44:82-55
6. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-77
7. Hatzivassiliou G, Song K, Yen I et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-55
8. Heidorn SJ, Milagre C, Whittaker S et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-211
9. MedaPharmaceuticals (2012) Summary of Product Characteristics http://www.medicines.org.uk//EMC/medicine/6219/SPC/Efudix+Cream//
10. Oberholzer PA, Kee D, Dziunycz P. et al. (2011) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-211
11. Poulikakos PI, Zhang C, Bollag G et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-300
12. Shimizu I, Cruz A, Chang KH et al. (2011) Treatment of squamous cell carcinoma in situ: A review. Dermatol Surg 37:1394-4111
13. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-144
14. Su F, Viros A, Milagre C et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-155